title: Efficacy of single large doses of caspofungin in a neutropenic murine model against the "psilosis" group.
abstract: We compared the in vivo efficacy of single large dose of caspofungin to that of daily smaller caspofungin doses (with same cumulative doses) against C. albicans (echinocandin susceptible and resistant isolates) and the â€œpsilosisâ€? group in a neutropenic murine model. Seven treatment groups were formed for C. orthopsilosis, C. metapsilosis and C. albicans (no treatment, 1, 2 and 3 mg/kg caspofungin daily for five days; single 5, 10 and 15 mg/kg caspofungin doses). For C. parapsilosis there were five treatment groups (no treatment, 3 and 4 mg/kg caspofungin daily for five days; single 15 and 20 mg/kg caspofungin). Tissue burdens of C. orthopsilosis and C. parapsilosis were significantly decreased by daily 3 mg/kg and 10 or 15 mg/kg single caspofungin doses (P<0.05-0.01) and daily 4 mg/kg and by single 15 and 20 mg/kg caspofungin doses (P<0.05-0.01), respectively. Against C. metapsilosis all treatment arms except the daily 1 mg/kg were effective (P<0.05-<0.001). Against C. albicans all treatment doses were effective. Neither daily 16 mg/kg nor single 80 mg/kg were effective against the resistant C. albicans strain. Higher doses and less frequent administration of caspofungin were comparable or sometimes superior to the lower, daily-dose regimen against the â€œpsilosisâ€? group supporting further studies with this therapeutic strategy.
authors.affiliation: Department of Medical Microbiology, Medical and Health Science Center, University of Debrecen, Hungary.
authors.forename: Réka
authors.initials: R
authors.lastname: Berényi
authors.forename: Renátó
authors.initials: R
authors.lastname: Kovács
authors.forename: Marianna
authors.initials: M
authors.lastname: Domán
authors.forename: Rudolf
authors.initials: R
authors.lastname: Gesztelyi
authors.forename: Gábor
authors.initials: G
authors.lastname: Kardos
authors.forename: Béla
authors.initials: B
authors.lastname: Juhász
authors.forename: David
authors.initials: D
authors.lastname: Perlin
authors.forename: László
authors.initials: L
authors.lastname: Majoros
mesh_terms: D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage*; D002175:Candida / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification; D002177:Candidiasis / Q000188:drug therapy* / Q000382:microbiology; D000077336:Caspofungin; D004195:Disease Models, Animal; D054714:Echinocandins / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D055666:Lipopeptides; D051379:Mice; D008807:Mice, Inbred BALB C; D009503:Neutropenia / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D000077336:Caspofungin